ITGB3 and nasopharyngeal carcinoma: Treatment with buthionine sulfoximine (BSO), a GSH synthesis inhibitor, and elesclomol, a ROS inducer, reversed the P-EVs- and ITGB3-enhanced NPC cell viability (Figure S3A).